A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

Phase 1 Completed 32 enrolled AstraZeneca

RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to assess safety, tolerability and pharmacokinetics of TC-5214 in medically stable elderly subjects following multiple oral doses.

Timeline

Start: 2011-01
Primary completion: 2011-05
Completion: 2011-05

Publications

Xu H, Henningsson A, Alverlind S, Tummala R, Toler S, Beaver JS, Al-Huniti N. Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies. J Clin Pharmacol. 2014 Jun;54(6):707-18. doi: 10.1002/jcph.264. Epub 2014 Jan 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dexmecamylamine	Other / unclassified	1 mg	Oral
Subject	dexmecamylamine	Other / unclassified	2 mg	Oral
Subject	dexmecamylamine	Other / unclassified	4 mg	Oral

Indications

No indication recorded.